

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
FEB 15 2002  
TECH CENTER 1600/2001

In re Application of:

Miri Seiberg, et al.

Serial No. 09/621,565

Filed: July 21, 2000

Art Unit: 1615

Examiner: B. Seidleck

Attorney Docket No.: JBP 510



REGULATING HAIR GROWTH, HAIR FOLLICLE AND HAIR SHAFT CELL AND HAIR PIGMENTATION

Commissioner for Patents  
Washington, D.C. 20231

Sir:

**REQUEST FOR RECONSIDERATION**

In response to the Office Action mailed on August 10, 2001, please consider the following remarks. Applicant respectfully requests reconsideration and allowance of the application.

Request for Extension of Time

Applicant respectfully requests that the shortened statutory period for response to the Outstanding Office Action dated August 10, 2001, set to expire on November 10, 2001, be extended by 3 months to expire on February 10, 2002. Enclosed is a check in the amount of Nine Hundred and Twenty Dollars (\$920.00) as required under 37 C.F.R. § 1.17(a)(3).

A

**AMENDMENT (Amendments noted)**

1. A method for effecting changes in mammalian hair appearance and hair pigmentation, and reducing hair growth, [hair pigmentation and] hair follicle and hair shaft size, comprising topical application to the skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
2. The method of claim 1 wherein said compound [extract] contains at least one serine protease inhibitory activity.

AMENDMENTS (Clean)

- Q
1. A method for effecting changes in mammalian hair appearance and hair pigmentation, and reducing hair growth, hair follicle and hair shaft size, comprising topical application to the skin of a mammal an effective amount of a topically active composition comprising one or more compounds derived from one or more of the botanical families leguminosae, solanaceae, gramineae and cucurbitaceae.
  2. The method of claim 1 wherein said compound contains at least one serine protease inhibitory activity.